Rutin-Loaded Stimuli-Responsive Hydrogel for Anti-Inflammation
Source abstract
Abstract
An active flavonoid compound rutin was incorporated into a guanosine phenylborate hydrogel (GBR) by a stimuli-responsive borate ester linkage for the treatment of inflammatory bowel disease (IBD). The components and morphology of the drug delivery system were characterized by NMR, UV–vis spectroscopy, and AFM. Rheological measurements revealed the required injectability and self-healing ability, which contributed to its application in rectal administration. The cell assays proved the excellent compatibility and safety of the system, and a possible pathway to form multicellular aggregates. In vitro drug-release studies showed that the hydrogel exhibited good stability in physiological medium, and the drug was almost completely released (more than 90 wt % after 24 h of incubation) in acidic pH and excessive ROS-containing medium, realizing the dual-responsive release of pH/ROS. In vivo activities of the GBR hydrogel showed higher therapeutic efficacy than free rutin in a colitis mice model, and it could significantly inhibit overexpressed inflammatory cytokines, including TNF-α and IL-6. Degradation studies of the hydrogel provided further evidence for the safety of its in vivo application. The work provided a simple strategy to prepare a G-quadruplex drug carrier, which was expected to achieve multi-drug delivery.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Supramolecular Self-Assembly in Materials · Lipid Membrane Structure and Behavior
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
State Key Laboratory of Chemical Resource Engineering, Beijing University of Chemical Technology, Beijing 100029, P. R. China
Digestive Disease Center, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing 100029, P. R. China
Funding
Beijing University of Chemical Technology · National Natural Science Foundation of China · China-Japan Friendship Hospital
References (52)
Show source-provided references
1. 10.1021/cr030204910.1021/cr0302049 ↗
2. 10.1039/c2cs35106d10.1039/c2cs35106d ↗
3. 10.1039/C5CS00093A10.1039/C5CS00093A ↗
4. 10.1039/b417081b10.1039/b417081b ↗
5. 10.1021/acs.chemrev.5b0029910.1021/acs.chemrev.5b00299 ↗
6. 10.1021/cr400195e10.1021/cr400195e ↗
7. 10.1039/b926219a10.1039/b926219a ↗
8. 10.1039/C3TB21016B10.1039/C3TB21016B ↗
9. 10.1021/ja507506c10.1021/ja507506c ↗
10. 10.1021/jacs.5b0275310.1021/jacs.5b02753 ↗
11. 10.1039/C6CC01494A10.1039/C6CC01494A ↗
12. 10.1021/jacs.7b0018610.1021/jacs.7b00186 ↗
13. 10.1021/acs.bioconjchem.7b0008010.1021/acs.bioconjchem.7b00080 ↗
14. 10.1021/acs.molpharmaceut.0c0124510.1021/acs.molpharmaceut.0c01245 ↗
15. 10.3389/fphar.2021.64438710.3389/fphar.2021.644387 ↗
16. 10.1016/j.msec.2019.11015910.1016/j.msec.2019.110159 ↗
17. 10.1517/13543784.2013.80574410.1517/13543784.2013.805744 ↗
18. 10.1007/s11010-016-2767-110.1007/s11010-016-2767-1 ↗
19. 10.1177/153537021347797510.1177/1535370213477975 ↗
20. 10.1002/adma.20150222710.1002/adma.201502227 ↗
21. 10.1016/j.cbi.2015.02.02110.1016/j.cbi.2015.02.021 ↗
22. 10.1007/s11064-016-1863-710.1007/s11064-016-1863-7 ↗
23. 10.1007/s00011-013-0689-x10.1007/s00011-013-0689-x ↗
24. 10.1186/s12906-016-1259-x10.1186/s12906-016-1259-x ↗
25. 10.1016/j.tifs.2017.07.00810.1016/j.tifs.2017.07.008 ↗
26. 10.1039/C4TB00702F10.1039/C4TB00702F ↗
27. 10.1021/acs.langmuir.9b0383710.1021/acs.langmuir.9b03837 ↗
28. 10.1039/D0RA05254J10.1039/D0RA05254J ↗
29. 10.1021/acs.joc.9b0271810.1021/acs.joc.9b02718 ↗
30. 10.3390/molecules1308193110.3390/molecules13081931 ↗
31. 10.3390/molecules2423426710.3390/molecules24234267 ↗
32. 10.1039/C7CC07806D10.1039/C7CC07806D ↗
33. 10.1021/acsbiomaterials.7b0056310.1021/acsbiomaterials.7b00563 ↗
34. 10.1039/D0BM00966K10.1039/D0BM00966K ↗
35. 10.1021/jacs.8b1048110.1021/jacs.8b10481 ↗
36. 10.1016/j.jnnfm.2016.11.00110.1016/j.jnnfm.2016.11.001 ↗
37. 10.1016/j.biomaterials.2019.11959810.1016/j.biomaterials.2019.119598 ↗
38. 10.1021/acsami.1c1421610.1021/acsami.1c14216 ↗
39. 10.1016/j.msec.2020.11183410.1016/j.msec.2020.111834 ↗
40. 10.1002/adhm.20190132910.1002/adhm.201901329 ↗
41. 10.1021/acsabm.9b0103410.1021/acsabm.9b01034 ↗
42. 10.1016/j.ijpharm.2011.10.04510.1016/j.ijpharm.2011.10.045 ↗
43. 10.1016/j.foodchem.2012.07.10410.1016/j.foodchem.2012.07.104 ↗
44. 10.3390/pharmaceutics1212118810.3390/pharmaceutics12121188 ↗
45. Gouda R. · J. Dev. Drugs · 2017 · 6 · 171
46. 10.1016/j.ijbiomac.2017.02.06110.1016/j.ijbiomac.2017.02.061 ↗
47. 10.1002/anie.20161035310.1002/anie.201610353 ↗
48. 10.1126/sciadv.aas899810.1126/sciadv.aas8998 ↗
49. 10.1039/C4CC03139C10.1039/C4CC03139C ↗
50. 10.1021/acsami.6b0491110.1021/acsami.6b04911 ↗
51. 10.1021/acs.jmedchem.9b0191210.1021/acs.jmedchem.9b01912 ↗
52. 10.3389/fphar.2017.0040010.3389/fphar.2017.00400 ↗